Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Halozyme Therapeutics Inc (NASDAQ:HALO)

9.94
Delayed Data
As of Jul 29
 +0.17 / +1.74%
Today’s Change
6.96
Today|||52-Week Range
25.00
-42.64%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 2
2015
Quarter 3
2015
Quarter 4
2015
Quarter 1
2016
Revenue and IncomeNet Revenues43.4M20.8M52.2M42.5M
 
 
 
 
 
Cost of Goods Sold7.7M5.8M8.0M7.3M
 
 
 
 
 
Depreciation And Amortization395.0K402.0K459.0K489.0K
 
 
 
 
 
 
Operating ExpensesGross Income35.2M14.6M43.8M34.7M
 
 
 
 
 
General Expenses31.0M37.8M38.3M50.9M
 
 
 
 
 
Research And Development21.2M27.6M27.7M40.1M
 
 
 
 
 
Total Operating Expenses39.2M44.0M46.8M58.7M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income4.2M-23.2M5.5M-16.2M
 
 
 
 
 
Interest Expense On Debt1.3M1.3M1.3M3.9M
 
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income3.0M-24.5M4.3M-19.8M
 
 
 
 
 
Net Income3.0M-24.5M4.3M-19.8M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS126.1M126.9M127.2M127.6M
 
 
 
 
 
Shares To Calculate EPS Diluted134.5M126.9M129.2M127.6M
 
 
 
 
 
 
Earnings Per ShareEPS$0.02-$0.19$0.03-$0.16
 
 
 
 
 
EPS Diluted$0.02-$0.19$0.03-$0.16